APO Research
Talk to an analyst

APO RESEARCH · REPORT

CINV Existing and Pipeline Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CINV Existing and Pipeline Drugs Market Outlook and Growth Opportunities 2026

20 December 2025192 pages

Choose your research edition.

Industry ResearchCINV Existing and Pipeline Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CINV Existing and Pipeline Drugs Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal CINV Existing and Pipeline Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CINV Existing and Pipeline Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CINV Existing and Pipeline Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global CINV Existing and Pipeline Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CINV Existing and Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CINV Existing and Pipeline Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CINV Existing and Pipeline Drugs market include Merck, GlaxoSmithKline, Tesaro, Heron Therapeutics and Helsinn, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CINV Existing and Pipeline Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CINV Existing and Pipeline Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CINV Existing and Pipeline Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CINV Existing and Pipeline Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

CINV Existing and Pipeline Drugs Segment by Company

Merck

GlaxoSmithKline

Tesaro

Heron Therapeutics

Helsinn

CINV Existing and Pipeline Drugs Segment by Type

Akynzeo

Aloxi

Emend

Kytril Generic

Rolapitant

SUSTOL

Zofran Generic

CINV Existing and Pipeline Drugs Segment by Application

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Hospitals

Drugstores

CINV Existing and Pipeline Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CINV Existing and Pipeline Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions CINV Existing and Pipeline Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CINV Existing and Pipeline Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze CINV Existing and Pipeline Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CINV Existing and Pipeline Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CINV Existing and Pipeline Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CINV Existing and Pipeline Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CINV Existing and Pipeline Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CINV Existing and Pipeline Drugs industry.

Chapter 3: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of CINV Existing and Pipeline Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CINV Existing and Pipeline Drugs Industry Trends Table 2. CINV Existing and Pipeline Drugs Industry Drivers Table 3. CINV Existing and Pipeline Drugs Industry Opportunities and Challenges Table 4. CINV Existing and Pipeline Drugs Industry Restraints Table 5. Global CINV Existing and Pipeline Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CINV Existing and Pipeline Drugs Revenue Share by Company (2021-2026) Table 7. Global CINV Existing and Pipeline Drugs Sales Volume by Company (Kg) & (2021-2026) Table 8. Global CINV Existing and Pipeline Drugs Sales Volume Share by Company (2021-2026) Table 9. Global CINV Existing and Pipeline Drugs Average Price (US$/Kg) of Company (2021-2026) Table 10. Global CINV Existing and Pipeline Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global CINV Existing and Pipeline Drugs Key Company Manufacturing Base & Headquarters Table 12. Global CINV Existing and Pipeline Drugs Company, Product Type & Application Table 13. Global CINV Existing and Pipeline Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global CINV Existing and Pipeline Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Akynzeo Table 18. Significant Companies of Aloxi Table 19. Significant Companies of Emend Table 20. Significant Companies of Kytril Generic Table 21. Significant Companies of Rolapitant Table 22. Significant Companies of SUSTOL Table 23. Significant Companies of Zofran Generic Table 24. Global CINV Existing and Pipeline Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 25. Global CINV Existing and Pipeline Drugs Sales Volume by Type (2021-2026) & (Kg) Table 26. Global CINV Existing and Pipeline Drugs Sales Volume by Type (2027-2032) & (Kg) Table 27. Global CINV Existing and Pipeline Drugs Sales Volume Share by Type (2021-2026) Table 28. Global CINV Existing and Pipeline Drugs Sales Volume Share by Type (2027-2032) Table 29. Global CINV Existing and Pipeline Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CINV Existing and Pipeline Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global CINV Existing and Pipeline Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global CINV Existing and Pipeline Drugs Sales Value Share by Type (2021-2026) Table 33. Global CINV Existing and Pipeline Drugs Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Specialty Clinics Table 35. Significant Companies of Diagnostic Centers Therapeutics Table 36. Significant Companies of Hospital Pharmacies Table 37. Significant Companies of Hospitals Table 38. Significant Companies of Drugstores Table 39. Global CINV Existing and Pipeline Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 40. Global CINV Existing and Pipeline Drugs Sales Volume by Application (2021-2026) & (Kg) Table 41. Global CINV Existing and Pipeline Drugs Sales Volume by Application (2027-2032) & (Kg) Table 42. Global CINV Existing and Pipeline Drugs Sales Volume Share by Application (2021-2026) Table 43. Global CINV Existing and Pipeline Drugs Sales Volume Share by Application (2027-2032) Table 44. Global CINV Existing and Pipeline Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global CINV Existing and Pipeline Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 46. Global CINV Existing and Pipeline Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 47. Global CINV Existing and Pipeline Drugs Sales Value Share by Application (2021-2026) Table 48. Global CINV Existing and Pipeline Drugs Sales Value Share by Application (2027-2032) Table 49. Global CINV Existing and Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 50. Global CINV Existing and Pipeline Drugs Sales by Region (2021-2026) & (Kg) Table 51. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2021-2026) Table 52. Global CINV Existing and Pipeline Drugs Sales by Region (2027-2032) & (Kg) Table 53. Global CINV Existing and Pipeline Drugs Sales Market Share by Region (2027-2032) Table 54. Global CINV Existing and Pipeline Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global CINV Existing and Pipeline Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 56. Global CINV Existing and Pipeline Drugs Sales Value Share by Region (2021-2026) Table 57. Global CINV Existing and Pipeline Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 58. Global CINV Existing and Pipeline Drugs Sales Value Share by Region (2027-2032) Table 59. Global CINV Existing and Pipeline Drugs Market Average Price (US$/Kg) by Region (2021-2026) Table 60. Global CINV Existing and Pipeline Drugs Market Average Price (US$/Kg) by Region (2027-2032) Table 61. Global CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 62. Global CINV Existing and Pipeline Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global CINV Existing and Pipeline Drugs Sales by Country (2021-2026) & (Kg) Table 64. Global CINV Existing and Pipeline Drugs Sales Market Share by Country (2021-2026) Table 65. Global CINV Existing and Pipeline Drugs Sales by Country (2027-2032) & (Kg) Table 66. Global CINV Existing and Pipeline Drugs Sales Market Share by Country (2027-2032) Table 67. Global CINV Existing and Pipeline Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 68. Global CINV Existing and Pipeline Drugs Sales Value Market Share by Country (2021-2026) Table 69. Global CINV Existing and Pipeline Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 70. Global CINV Existing and Pipeline Drugs Sales Value Market Share by Country (2027-2032) Table 71. Merck Company Information Table 72. Merck Business Overview Table 73. Merck CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 74. Merck CINV Existing and Pipeline Drugs Product Portfolio Table 75. Merck Recent Development Table 76. GlaxoSmithKline Company Information Table 77. GlaxoSmithKline Business Overview Table 78. GlaxoSmithKline CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 79. GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio Table 80. GlaxoSmithKline Recent Development Table 81. Tesaro Company Information Table 82. Tesaro Business Overview Table 83. Tesaro CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 84. Tesaro CINV Existing and Pipeline Drugs Product Portfolio Table 85. Tesaro Recent Development Table 86. Heron Therapeutics Company Information Table 87. Heron Therapeutics Business Overview Table 88. Heron Therapeutics CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 89. Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio Table 90. Heron Therapeutics Recent Development Table 91. Helsinn Company Information Table 92. Helsinn Business Overview Table 93. Helsinn CINV Existing and Pipeline Drugs Sales (Kg), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 94. Helsinn CINV Existing and Pipeline Drugs Product Portfolio Table 95. Helsinn Recent Development Table 96. Key Raw Materials Table 97. Raw Materials Key Suppliers Table 98. CINV Existing and Pipeline Drugs Distributors List Table 99. CINV Existing and Pipeline Drugs Customers List Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. CINV Existing and Pipeline Drugs Product Image Figure 2. Global CINV Existing and Pipeline Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global CINV Existing and Pipeline Drugs Sales (2021-2032) & (Kg) Figure 5. Global CINV Existing and Pipeline Drugs Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global CINV Existing and Pipeline Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Akynzeo Image Figure 10. Aloxi Image Figure 11. Emend Image Figure 12. Kytril Generic Image Figure 13. Rolapitant Image Figure 14. SUSTOL Image Figure 15. Zofran Generic Image Figure 16. Global CINV Existing and Pipeline Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 17. Global CINV Existing and Pipeline Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global CINV Existing and Pipeline Drugs Sales Volume Share by Type (2021-2032) Figure 19. Global CINV Existing and Pipeline Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CINV Existing and Pipeline Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global CINV Existing and Pipeline Drugs Sales Value Share by Type (2021-2032) Figure 22. Specialty Clinics Image Figure 23. Diagnostic Centers Therapeutics Image Figure 24. Hospital Pharmacies Image Figure 25. Hospitals Image Figure 26. Drugstores Image Figure 27. Global CINV Existing and Pipeline Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 28. Global CINV Existing and Pipeline Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 29. Global CINV Existing and Pipeline Drugs Sales Volume Share by Application (2021-2032) Figure 30. Global CINV Existing and Pipeline Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 31. Global CINV Existing and Pipeline Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 32. Global CINV Existing and Pipeline Drugs Sales Value Share by Application (2021-2032) Figure 33. Global CINV Existing and Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 34. Global CINV Existing and Pipeline Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 35. Global CINV Existing and Pipeline Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 36. Global CINV Existing and Pipeline Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 37. North America CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. North America CINV Existing and Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Europe CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Europe CINV Existing and Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Asia-Pacific CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Asia-Pacific CINV Existing and Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. South America CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. South America CINV Existing and Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. Middle East & Africa CINV Existing and Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 46. Middle East & Africa CINV Existing and Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 47. USA CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. USA CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. USA CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Canada CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Canada CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Canada CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Mexico CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Mexico CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Mexico CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Germany CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Germany CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Germany CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. France CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. France CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. France CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. U.K. CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. U.K. CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. U.K. CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Italy CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Italy CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Italy CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Spain CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Spain CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Spain CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Russia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Russia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Russia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Netherlands CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Netherlands CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Netherlands CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Nordic Countries CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Nordic Countries CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Nordic Countries CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. China CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. China CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. China CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Japan CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Japan CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Japan CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. South Korea CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. South Korea CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. South Korea CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. India CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. India CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. India CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Australia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Australia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Australia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Southeast Asia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Southeast Asia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Southeast Asia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Brazil CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Brazil CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Brazil CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Argentina CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Argentina CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Argentina CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Chile CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Chile CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Chile CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Colombia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Colombia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Colombia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Peru CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Peru CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Peru CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Israel CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Israel Arabia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Israel Arabia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. UAE CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. UAE CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. UAE CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Turkey CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Turkey CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Turkey CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Iran CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Iran CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Iran CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Egypt CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Egypt CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Egypt CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. CINV Existing and Pipeline Drugs Value Chain Figure 132. Manufacturing Cost Structure Figure 133. CINV Existing and Pipeline Drugs Sales Mode & Process Figure 134. Direct Comparison with Distribution Share Figure 135. Distributors Profiles Figure 136. Years Considered Figure 137. Research Process Figure 138. Key Executives Interviewed

Scope & coverage.

Types
  • Akynzeo
  • Aloxi
  • Emend
  • Kytril Generic
  • Rolapitant
  • SUSTOL
  • Zofran Generic
Applications
  • Specialty Clinics
  • Diagnostic Centers Therapeutics
  • Hospital Pharmacies
  • Hospitals
  • Drugstores
Companies covered
  • Merck
  • GlaxoSmithKline
  • Tesaro
  • Heron Therapeutics
  • Helsinn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  4. 1.2.2 Global CINV Existing and Pipeline Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global CINV Existing and Pipeline Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 CINV Existing and Pipeline Drugs Market Dynamics
  1. 2.1 CINV Existing and Pipeline Drugs Industry Trends
  2. 2.2 CINV Existing and Pipeline Drugs Industry Drivers
  3. 2.3 CINV Existing and Pipeline Drugs Industry Opportunities and Challenges
  4. 2.4 CINV Existing and Pipeline Drugs Industry Restraints
3 CINV Existing and Pipeline Drugs Market by Company
  1. 3.1 Global CINV Existing and Pipeline Drugs Company Revenue Ranking in 2025
  2. 3.2 Global CINV Existing and Pipeline Drugs Revenue by Company (2021-2026)
  3. 3.3 Global CINV Existing and Pipeline Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global CINV Existing and Pipeline Drugs Average Price by Company (2021-2026)
  5. 3.5 Global CINV Existing and Pipeline Drugs Company Ranking (2024-2026)
  6. 3.6 Global CINV Existing and Pipeline Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global CINV Existing and Pipeline Drugs Company Product Type and Application
  8. 3.8 Global CINV Existing and Pipeline Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global CINV Existing and Pipeline Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 CINV Existing and Pipeline Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 CINV Existing and Pipeline Drugs Market by Type
  1. 4.1 CINV Existing and Pipeline Drugs Type Introduction
  2. 4.1.1 Akynzeo
  3. 4.1.2 Aloxi
  4. 4.1.3 Emend
  5. 4.1.4 Kytril Generic
  6. 4.1.5 Rolapitant
  7. 4.1.6 SUSTOL
  8. 4.1.7 Zofran Generic
  9. 4.2 Global CINV Existing and Pipeline Drugs Sales Volume by Type
  10. 4.2.1 Global CINV Existing and Pipeline Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global CINV Existing and Pipeline Drugs Sales Volume by Type (2021-2032)
  12. 4.2.3 Global CINV Existing and Pipeline Drugs Sales Volume Share by Type (2021-2032)
  13. 4.3 Global CINV Existing and Pipeline Drugs Sales Value by Type
  14. 4.3.1 Global CINV Existing and Pipeline Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global CINV Existing and Pipeline Drugs Sales Value by Type (2021-2032)
  16. 4.3.3 Global CINV Existing and Pipeline Drugs Sales Value Share by Type (2021-2032)
5 CINV Existing and Pipeline Drugs Market by Application
  1. 5.1 CINV Existing and Pipeline Drugs Application Introduction
  2. 5.1.1 Specialty Clinics
  3. 5.1.2 Diagnostic Centers Therapeutics
  4. 5.1.3 Hospital Pharmacies
  5. 5.1.4 Hospitals
  6. 5.1.5 Drugstores
  7. 5.2 Global CINV Existing and Pipeline Drugs Sales Volume by Application
  8. 5.2.1 Global CINV Existing and Pipeline Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global CINV Existing and Pipeline Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global CINV Existing and Pipeline Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global CINV Existing and Pipeline Drugs Sales Value by Application
  12. 5.3.1 Global CINV Existing and Pipeline Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global CINV Existing and Pipeline Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global CINV Existing and Pipeline Drugs Sales Value Share by Application (2021-2032)
6 CINV Existing and Pipeline Drugs Regional Sales and Value Analysis
  1. 6.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CINV Existing and Pipeline Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global CINV Existing and Pipeline Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global CINV Existing and Pipeline Drugs Sales by Region (2027-2032)
  5. 6.3 Global CINV Existing and Pipeline Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global CINV Existing and Pipeline Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global CINV Existing and Pipeline Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global CINV Existing and Pipeline Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global CINV Existing and Pipeline Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  12. 6.6.2 North America CINV Existing and Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe CINV Existing and Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  21. 6.9.2 South America CINV Existing and Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa CINV Existing and Pipeline Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa CINV Existing and Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
7 CINV Existing and Pipeline Drugs Country-level Sales and Value Analysis
  1. 7.1 Global CINV Existing and Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CINV Existing and Pipeline Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global CINV Existing and Pipeline Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global CINV Existing and Pipeline Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global CINV Existing and Pipeline Drugs Sales by Country (2027-2032)
  6. 7.4 Global CINV Existing and Pipeline Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global CINV Existing and Pipeline Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global CINV Existing and Pipeline Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt CINV Existing and Pipeline Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt CINV Existing and Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt CINV Existing and Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck CINV Existing and Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck CINV Existing and Pipeline Drugs Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Tesaro
  14. 8.3.1 Tesaro Company Information
  15. 8.3.2 Tesaro Business Overview
  16. 8.3.3 Tesaro CINV Existing and Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tesaro CINV Existing and Pipeline Drugs Product Portfolio
  18. 8.3.5 Tesaro Recent Developments
  19. 8.4 Heron Therapeutics
  20. 8.4.1 Heron Therapeutics Company Information
  21. 8.4.2 Heron Therapeutics Business Overview
  22. 8.4.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Heron Therapeutics CINV Existing and Pipeline Drugs Product Portfolio
  24. 8.4.5 Heron Therapeutics Recent Developments
  25. 8.5 Helsinn
  26. 8.5.1 Helsinn Company Information
  27. 8.5.2 Helsinn Business Overview
  28. 8.5.3 Helsinn CINV Existing and Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Helsinn CINV Existing and Pipeline Drugs Product Portfolio
  30. 8.5.5 Helsinn Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CINV Existing and Pipeline Drugs Value Chain Analysis
  2. 9.1.1 CINV Existing and Pipeline Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CINV Existing and Pipeline Drugs Sales Mode & Process
  6. 9.2 CINV Existing and Pipeline Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CINV Existing and Pipeline Drugs Distributors
  9. 9.2.3 CINV Existing and Pipeline Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst